Report

Roche's Bispecific Antibody Drug Emicizumab Patent Research and Practical Operation Guide

Roche's Bispecific Antibody Drug Emicizumab Patent Research and Practical Operation Guide

Emicizumab (Hemlibra) is a bispecific antibody developed by Roche that targets coagulation factors IXa and X. It was first approved by the FDA in November 2017 and received an expanded indication in 2018 for the prophylactic treatment of bleeding in hemophilia A patients, regardless of inhibitor status. This bispecific therapeutic is currently the only bispecific antibody drug used in the field of hemophilia. Since its market launch, Emicizumab has experienced a compound annual growth rate exceeding 300%, with sales surpassing $2 billion by 2020, thus becoming a blockbuster drug. In 2023, Hemlibra reported sales of CHF 4.147 billion (approximately $4.575 billion), reflecting a 16% year-over-year growth. The growth trajectory continues into 2024, with first-half sales reaching CHF 2.143 billion (approximately $2.529 billion). Sales are projected to reach $6.203 billion by 2028. As the highest-grossing bispecific antibody drug currently on the market, Emicizumab's patent landscape garners significant interest. This report aims to guide readers through a step-by-step patent analysis of the Emicizumab drug, ultimately providing a detailed patent landscape map. This can serve as a reference and provide insights for patent strategy in the bispecific antibody field.

Read →
GPRC5D Target Patent Research Report

GPRC5D Target Patent Research Report

Multiple myeloma (MM) is a stubborn disease that remains incurable. In recent years, targeted therapies against B-cell maturation antigen (BCMA) have shown promising responses in a substantial number of treated patients. However, the global relapse rate among myeloma patients following anti-BCMA treatment strategies is on the rise. This necessitates continuous exploration of therapies with novel mechanisms of action and new targets, one of which is the G protein-coupled receptor family C group 5 member D (GPRC5D). Due to its unique expression in the plasma cell lineage of MM patients, along with positive data from targeted chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (BsAb), GPRC5D has emerged as an ideal target for anti-myeloma antibodies. The latest "GPRC5D Target Patent Research Report" from Patsnap Lifescience offers an in-depth analysis of global R&D trends related to the GPRC5D target. The report indicates that besides the already marketed Talquetamab, there are 38 drugs currently in clinical or preclinical stages. The R&D trends and market prospects of these drugs are poised to be critical to the future of MM treatment. In terms of patent coverage, the GPRC5D target enjoys a long protection period, providing development companies with prolonged R&D incentives and market exclusivity. The report not only covers the core patent status of approved drugs but also estimates the patent protection periods for clinical stage drugs, offering significant references for R&D decision-making within the industry. Additionally, the report highlights the exploration of combination therapies involving GPRC5D-targeted drugs and their potential applications in other plasma cell disorders, thus providing new perspectives for the future direction of MM treatment. As more companies invest in the development of innovative drugs targeting GPRC5D, we believe this target will offer more treatment options and hope to MM patients.

Read →
siRNA Drug Amvuttra Patent Research and Practical Operation Guide

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Small interfering RNA (siRNA) are short double-stranded RNA molecules, typically 21-25 nucleotides long. On June 13, 2022, Alnylam's siRNA drug Amvuttra® (Vutrisiran) was approved by the FDA for treating polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. As Alnylam's flagship product, Amvuttra generated $560 million in sales in 2023. Compared to Alnylam's Onpattro, Amvuttra has lower manufacturing costs, requires less frequent dosing, and offers convenient subcutaneous injection, potentially leading more patients to switch to Amvuttra. Over 20 companies globally are developing siRNA drugs, but Alnylam dominates the market with a robust patent strategy covering Amvuttra's core components, delivery agents, sequences, and modifications. Alnylam utilizes divisional and continuation applications to maintain extensive patent protection, serving as a model for siRNA drug patenting. This report focuses on siRNA drug patent searches, using Alnylam's Amvuttra as a case study to illustrate the research process. It also provides an overview of the latest patent landscapes in the U.S. and China.

Read →
Patent Research and Operational Guide for Daiichi Sankyo's ADC Drug DS-8201

Patent Research and Operational Guide for Daiichi Sankyo's ADC Drug DS-8201

Antibody-Drug Conjugates (ADCs) have a tripartite structure: Antibody-Linker-Payload. Currently, 272 ADCs are in clinical trials worldwide. Despite the withdrawal of Belantamab mafodotin, 14 ADCs remain on the market. ADC development is highly competitive, with strategic patent deployment being critical. For example, DS-8201's patents on each component offer primary protection, while novel combinations and pharmacological properties drive patent iteration and extend market exclusivity. Comprehensive extraction and aggregation of these source, core, and iterative patents are essential for high-quality patent research reports to guide infringement analysis, biosimilar development, and investment strategies. This report focuses on ADC patent searches, using DS-8201 as a case study to outline the research process and map the latest patent landscapes in China and the United States.

Read →
BeiGene's Patent Research and Practical Operation Guide for Tislelizumab

BeiGene's Patent Research and Practical Operation Guide for Tislelizumab

In recent years, the rise of biologics is an established fact. Antibody drugs, such as Merck's PD-1 monoclonal antibody Keytruda, have become top-sellers. As a result, patent research on antibody drugs has gained importance. The goal is to compile comprehensive and accurate patent information to support infringement analysis, biosimilar development, investment, and R&D. High-quality patent research reports on antibody drugs now represent a core competitive advantage, playing a crucial role at various corporate stages. This research involves several coordinated steps: patent search, patent screening, clinical analysis, and concluding recommendations. The following sections will detail these steps.

Read →
A Guide to Investigating Aflibercept Sequence Patents

A Guide to Investigating Aflibercept Sequence Patents

The "A Guide to Investigating Aflibercept Sequence Patents" provides an in-depth analysis of global Aflibercept sequence patents through detailed research. The guide consists of five sections: Preface, Introduction to Aflibercept, Practical Patent Search, Patent Analysis, and Conclusion. It aims to instruct readers on using the Bio database for drug sequence patent search and analysis. In August 2023, Regeneron Pharmaceuticals announced FDA approval for an 8 mg injection of Eylea (Aflibercept) for wAMD, DME, and DR, extending the injection interval from two months to four months. Initially approved in 2011, Eylea was developed by Regeneron and Bayer. Aflibercept is a fully human recombinant fusion protein that inhibits angiogenesis and vascular permeability by binding VEGF-A, VEGF-B, and PlGF. Its indications include ophthalmic diseases and metastatic colorectal cancer. To aid biomedical researchers in understanding Aflibercept's global development and IP protection, the guide leverages the Patsnap Bio sequence database. It covers practical aspects of sequence patent searches, including retrieval methods and analytical techniques. The guide further analyzes the global status and core patents of Aflibercept, providing comprehensive insights on its patent landscape.

Read →
Conjugate Targeted Drug Delivery Research

Conjugate Targeted Drug Delivery Research

The report provides a rapid review and market overview of the global conjugate targeted drug delivery research, with a professional analysis of technology and barriers, including an in-depth analysis of national policies and an excellent summary of applications and patents.

Read →
Inhalation Preparations Drug Delivery Research

Inhalation Preparations Drug Delivery Research

The report provides a rapid review and market overview of the global inhalation preparations drug delivery industry, with professional analysis of technology and barriers, including an in-depth analysis of national policies and an excellent summary of applications and patents.

Read →